FibroBiologics Files 8-K: Agreements, Obligations, and Equity Sales
Ticker: FBLG · Form: 8-K · Filed: Dec 23, 2024 · CIK: 1958777
Sentiment: neutral
Topics: material-agreement, financial-obligation, equity-sale
TL;DR
FibroBiologics dropped an 8-K detailing new agreements, financial obligations, and equity sales.
AI Summary
On December 20, 2024, FibroBiologics, Inc. entered into a material definitive agreement related to a direct financial obligation. The company also reported on the creation of a direct financial obligation or an off-balance sheet arrangement and unregistered sales of equity securities. This filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
Why It Matters
This 8-K filing indicates significant financial activities and potential future obligations for FibroBiologics, Inc., which could impact its financial standing and stock performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, financial obligations, and unregistered equity sales, which can introduce financial and operational risks.
Key Players & Entities
- FibroBiologics, Inc. (company) — Registrant
- December 20, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did FibroBiologics, Inc. enter into?
The filing indicates the entry into a material definitive agreement related to a direct financial obligation, but the specific details of the agreement are not provided in the provided text.
What are the key items reported in this 8-K filing?
The key items reported are the entry into a material definitive agreement, the creation of a direct financial obligation or an off-balance sheet arrangement, unregistered sales of equity securities, Regulation FD Disclosure, and Financial Statements and Exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on December 20, 2024.
What is the state of incorporation for FibroBiologics, Inc.?
FibroBiologics, Inc. is incorporated in Delaware.
What is the SIC code for FibroBiologics, Inc.?
The Standard Industrial Classification (SIC) code for FibroBiologics, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 2,413 words · 10 min read · ~8 pages · Grade level 13.3 · Accepted 2024-12-23 08:00:16
Key Financial Figures
- $0.00001 — ichregistered Common stock, par value $0.00001 per share FBLG Nasdaq Global Marke
- $15 million — forth therein, the principal amount of $15 million (the "Pre-Paid Advance"), which will be
- $100,000 — 19, 2026 by paying an extension fee of $100,000, and to February 18, 2026 by paying an
- $2.41 — version price equal to the lower of (i) $2.41 per share or (ii) 94% of the lowest dai
- $5 million — ber 20, 2024 in the principal amount of $5 million. The second tranche of the Pre-Paid Adv
- $10 million — nvestor to purchase up to an additional $10 million of shares of Common Stock (the "Commitm
- $25,000 — paid the Investor a structuring fee of $25,000 and agreed to pay the Investor a commit
- $250,000 — the Investor a commitment fee totaling $250,000 (the "Commitment Fee"). The Commitment
Filing Documents
- form8-k.htm (8-K) — 58KB
- ex10-1.htm (EX-10.1) — 301KB
- ex10-2.htm (EX-10.2) — 155KB
- ex10-3.htm (EX-10.3) — 106KB
- ex99-1.htm (EX-99.1) — 15KB
- ex99-1_001.jpg (GRAPHIC) — 16KB
- 0001493152-24-051209.txt ( ) — 953KB
- fblg-20241220.xsd (EX-101.SCH) — 3KB
- fblg-20241220_lab.xml (EX-101.LAB) — 33KB
- fblg-20241220_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On December 23, 2024, the Company issued a press release announcing the transaction with the Investor. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed incorporated by reference into any other filing, except as shall be expressly set forth by specific reference in such a filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits 10.1 Standby Equity Purchase Agreement, dated December 20, 2024, between FibroBiologics, Inc. and YA II PN, LTD. 10.2 Convertible Promissory Note, dated December 20, 2024, between FibroBiologics, Inc. and YA II PN, LTD. 10.3 Registration Rights Agreement, dated December 20, 2024, between FibroBiologics, Inc. and YA II PN, LTD. 99.1 Press Release, dated December 23, 2024 Exhibit 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Date: December 23, 2024 FibroBiologics, Inc. By: /s/ Pete O'Heeron Name: Pete O'Heeron Title: Chief Executive Officer